Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment by Lê, Phu Quoc et al.
Survival Among Children and Adults With Sickle Cell Disease in Belgium: Beneﬁt
From Hydroxyurea Treatment
PhuQuoc Le^, MD,1 Beatrice Gulbis, MD,PhD,2 LaurenceDedeken, MD,1 Sophie Dupont, MD,3 Anna Vanderfaeillie, MD,4
Catherine Heijmans, MD,1,5 Sophie Huybrechts, MD,1 Christine Devalck, MD,1 Andre Eﬁra, MD,6
Marie-FranScoise Dresse, MD, PhD,7 Laurence Rozen,8 Fleur Samantha Benghiat, MD, PhD,9 and Alina Ferster, MD1
INTRODUCTION
In Western countries, mortality among children with sickle cell
disease (SCD) has decreased in the last few decades.Major advances
in this ﬁeld are the result of the implementation of preventive
measures and mainly linked to the introduction in the 1980s of the
systematic penicillin prophylaxis[1] and vaccinations to prevent
pneumococcal and Haemophilus inﬂuenza type b diseases.[2–7]
Systematic newborn screening, parents’ education, and comprehen-
sive care programs have also greatly contributed to reduce childhood
mortality.[8] More recently transcranial Doppler ultrasonography
screening allows identifying asymptomatic patients at high risk for
stroke.[9] In them, chronic transfusion support is now recognized as a
major breakthrough in stroke prevention.[10,11] From several
clinically based series we know that more than 95% of children
with SCDare expected to reach adulthood.[12–16]The other 5%dies
mainly from acute chest syndrome (ACS), sepsis, splenic sequestra-
tion, stroke, and aplastic crisis. For those who reach adulthood, an
additional cause of death is end-stage organ failure.[17–21]
Survival in the Belgian population with SCD has never been
studied. A national database recording these patients was created in
2008andoffersa unique tool to address this question.The introduction,
more than 20 years ago in Belgium, of treatments such as hydroxyurea
(HU) and hematopoietic stem cell transplantation (HSCT), but also
the partial implementation of a newborn screening program, might
have modiﬁed this survival rate. The objectives of this study were to
evaluate themortality rate and the causes of death among the registered
Belgian patients with SCD, and to determine the possible impact of
disease-modifying therapies on that mortality rate.
PATIENTS AND METHODS
Setting
No ofﬁcial national registry of patients with SCD existed in
Belgium. In October 2008, under the auspices of the Belgian
Hematological Society, members of its Red Blood Cells committee
decided to set up a SCD patients’ database. Treating hematologists
were invited to participate on a voluntary basis and to register their
patients into the national database. The database included all
patients who regularly followed in the clinical center. The Belgian
SCD Registry currently includes patients from eight centers either
adult or pediatric. Among them, two are secondary and six are
Abbreviations: ACS, acute chest syndrome; CI, conﬁdence interval;
DMT, disease-modifying treatment; Hb, hemoglobin; HSCT, hemato-
poietic stem cell transplantation; HU, hydroxyurea; NSP, newborn
screening programme; PY, patient-year; SCD, sickle cell disease; SE,
standard error; US, United States of America; VOC, vaso occlusive
crisis
1Hemato-Oncology Unit, Ho^pital Universitaire des Enfants Reine
Fabiola, U.L.B., Brussels, Belgium; 2Department of Clinical Chemis-
try, Ho^pital Erasme, U.L.B., Brussels, Belgium; 3Hemato-Oncology
Unit, Cliniques Universitaires Saint Luc, Brussels, Belgium; 4Depart-
ment of Pediatrics, Ho^pital Saint-Pierre, U.L.B., Brussels, Belgium;
5Department of Pediatrics, Ho^pital de Jolimont, La Louviere, Belgium;
6Hemato-Oncology Unit, Ho^pital Universitaire Brugmann, U.L.B.,
Brussels, Belgium; 7Hemato-Oncology Unit, Ho^pital Regional de la
Citadelle, ULg, Liege, Belgium; 8Laboratory of Hematology, CHU-
Brugmann, Ho^pital Universitaire des Enfants Reine Fabiola, U.L.B.,
Brussels, Belgium; 9Hemato-Oncology Unit, Ho^pital Erasme, U.L.B.,
Brussels, Belgium
Grant sponsor: Fonds IRIS-Recherche Brussels; Grant sponsor:
Novartis Pharma Belgium
Conﬂicts of interest statement: The authors have no competing
interests.
Correspondence to: Phu Quoc Le^, Department of Hemato-oncology,
Ho^pital Universitaire des Enfants Reine Fabiola, 15 Avenue Jean
Joseph Crocq, 1020 Brussels, Belgium. E-mail: phuquoc.le@huderf.be
Received 14 January 2015; Accepted 22 April 2015
Objective. To evaluate the survival of patients with sickle cell
disease (SCD) recorded in the Belgian SCD Registry and to assess the
impact of disease-modifying treatments (DMT).Method. The Registry
created in 2008 included patients of eight centers. All available data
in 2008were retrospectively encoded in the database. After 2008 and
until 2012, all data were recorded prospectively for already
registered patients as well as newly diagnosed subjects. Data were
registered from neonatal screening or from diagnosis (ﬁrst contact)
until last follow-up or death. Data included diagnosis, demography,
and outcome data. Results.We collected data from 469 patients over
a 5,110 patient years (PY) follow-up period. The global mortality rate
was low (0.25/100 PY), although 13 patients died (2.8%) and was
similar between children, adolescents (10–18 years), and young
adults (P¼0.76). Out of the cohort, 185 patients received
hydroxyurea at last follow-up (median duration of treatment: 10.3
years), 90 underwent hematopoietic stem cell transplantation
(HSCT), 24 were chronically transfused, and 170 had never had
any DMT. Hydroxyurea showed signiﬁcant beneﬁt on patients
outcome as reﬂected by a lower mortality rate compared to
transplanted individuals or people without DMT (0.14, 0.36, and
0.38 per 100 PY, respectively) and by higher Kaplan–Meier estimates
of 15 year survival (99.4%) compared to HSCT (93.8%; P¼0.01) or
no DMT groups (95.4%; P¼0.04). Conclusion. SCD mortality in
Belgium is low with no increase observed in young adults. Patients
treatedwith hydroxyurea demonstrate a signiﬁcant beneﬁt in survival
when compared to thosewithoutDMT or transplanted. Pediatr Blood
Cancer © 2015 Wiley Periodicals, Inc.
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tertiary care centers. Six of them provide care to children and two to
adult patients.
In Belgium, a universal newborn screening program (NSP) for
hemoglobinopathies began in Brussels Region in 1994 and in Liege
Region in 2001. Today, neonatal screening is thus now offered to
about one-third of Belgian newborns.
Once patients with SCD were identiﬁed, their regular follow-up
in the participating centers was applied according to the policy of
each center. All the patients were prescribed oral antibiotic
prophylaxis at least up to ﬁve years of age. The usual immunization
schedules according to the national recommendations were
provided, including conjugate vaccines against Haemophilus
inﬂuenzae type b (four doses) since 1994 and conjugated
Streptococcus pneumoniae (three doses) since 2004. Starting in
1999, transcranial Doppler ultrasonography has been progressively
included in the regular follow-up. Disease modifying therapies
(DMT) such as hydroxyurea,[22–25] chronic transfusion, and
hematopoietic stem cell transplantation[26–30] were introduced
according to each center’s policy but following the usual indications
that have been detailed in previous international publications.
[25,31–33] National recommendations on SCD management were
only recently implemented in Belgium. In almost all centers, the
management of the patients was implemented gradually as a
comprehensive care program with emphasis on education, preven-
tion, and patient empowerment.
Data Collection
A secured computer-based database for all patients with SCD
followed in Belgium was created in 2008. For this study, the
database was locked in December 2012 and the ﬁrst author of the
study collected all data. Each local ethics committee approved data
collection and the registry according to the Declaration of Helsinki.
To ensure patient conﬁdentiality, data were processed in compli-
ance with legal requirements and privacy guidelines. Informed
consent was obtained from all patients (or their parents/legal
guardians). For patients who died before 2008, retrospective data
collection was used. Patients’ data that predates 2008 were
extracted from the medical records while from 2008 data were
directly entered into the database. Data were collected either from
birth or from the diagnosis depending on whether the patients
beneﬁted from the newborn screening program or not, and until the
last follow-up visit, or death of the patient. The database includes
diagnosis (date, method, and genotype), demographic data, SCD-
related events, hospitalizations, immunizations, steady-state bio-
logical parameters, data on chronic organ damage (i.e., cerebral
vasculopathy, renal failure), treatments, vital status, and cause of
death. For patients lost to follow-up, last available data are from the
last visit. After HSCT, only vital status was recorded as well as the
cause of death if applicable. Patients transplanted before 1985
without complete data set or not living in Belgium before HSCT
were not included in this analysis (n¼ 10).
Statistical Analysis
Categorical and continuous variables were analyzed with
Graphpad Prism1 software 5.0 (Graphpad Software, Inc., San
Diego, CA). Kruskal–Wallis test was used to compare continuous
data of multiple groups expressed as median whereas Dunn’s
Multiple comparison test was used to compare data of pairs of
groups. x2 and Fisher’s tests were used to compare data expressed as
proportions.
Kaplan–Meier and their 95% conﬁdence interval (95%CI) were
calculated. Group survivals were compared by the log-rank test.
The different survival curves of HU, HSCT, and no DMT were
compared by the same log-rank test and the P-value was adjusted
for multiple testing by the Bonferroni method. Because patients
may have had successive treatments, we tested with a Cox
regression model if a time-varying effect was signiﬁcantly
associated with survival. A P-value less than 0.05 for socio-
demographic differences between the groups was considered
statistically signiﬁcant. Statistical signiﬁcance was attained when
a P-value was less than 0.0167 for multiple testing by the
Bonferroni method.
RESULTS
Up to December 2012, 469 patients were registered in the
database. The main characteristics of the patients are depicted in
Tables I and II, respectively. Among the 5,110 patient-years of
follow-up, 1,242 accounted for patients diagnosed by newborn
screening. The global mortality rate was 0.25/100 patient-years; 13
patients died (2.8%). The mortality rate of the neonatal screened
cohort was 0.16/100 patient-years and was 0.28/100 patient-years
in the non-neonatal screening cohort (P¼ 0.67). Mortality rate was
similar between children, adolescents (10–18 years), and young
adults (P¼ 0.76). All deaths occurred in HbSS patients, ﬁve after
HSCT (three from acute transplant related toxicity, one from
secondary acute myeloblastic leukemia after chronic graft vs. host
disease four years after transplantation, and one unexplained death
occurred more than seven years post HSCT), and eight were related
to an acute event (three from hemorrhagic strokes, one from sepsis
due to S. pneumoniae, one from aplastic crisis, one from cardiac
failure associated with tetralogy of Fallot, one sepsis associated
with leg ulcer, and one infection during travel in Africa). All
patients were under antibiotic prophylaxis. Three patients who died
from hemorragic stroke were not followed by routine transcranial
Doppler; their vasculopathy was inaugural (Table III).
Ninety patients underwent HSCT.Median age at transplantation
was 6.9 years (range: 1–19 years). Among the non-transplant
TABLE I. Characteristics of the SCD Population, Follow-Up













<10 years 186 974 0.41
10–18 years 144 1,557 0.32
>18 years 139 2,579 0.16
Genotypes
HbSSþHbSb˚ 423 4,749 0.27
<10 years 163 846 0.47
10–18 years 128 1,411 0.35
>18 years 132 2,492 0.16
HbSC 36 292 0
HbSbþ 7 54 0
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patients, 185 were on HU at last follow up for a median duration of
10.3 years (range: 0.1–35 years) and 24 were on chronic transfusion
regimen (4 after HU treatment). The reasons for HU prescriptions
were 2 vaso occlusive crisis (VOC) per year requiring
hospitalization (110 patients), 2 episodes of ACS (n¼ 33),
recurrent splenic sequestration (n¼ 6), recurrent dactylitis (n¼ 7),
stroke or transient ischemic attack (n¼ 2) with red blood cell
alloimmunization impairing chronic transfusion, and abnormal
transcranial Doppler ultrasonography (n¼ 27). The remaining 170
patients never received DMT. Patients treated with HU were
signiﬁcantly older at diagnosis, had a longer follow-up, and lower
death rate/100 patient years than those with no DMT. Patients who
underwent HSCT had not a more severe clinical disease than those
treated with HU. The indications to start HU treatment or to perform
HSCT were VOC, respectively, in 110/185 and 40/90 patients
(P¼ 0.02), recurrent ACS in 33/185 and 17/90 patients (P¼ 0.87),
and abnormal blood ﬂow velocities in cerebral arteries in 27/180
and 13/90 (P¼ 1). Two patients have had stroke in both groups.
The 15-year overall survival of the entire cohort was 96.9%
(95%CI: 95–99; SE¼ 0.95%) but varied signiﬁcantly according to
the treatment given (Fig. 1). Mortality rates for HU, no DMT, and
HSCT groups were 0.14, 0.38, and 0.36 per 100 patient years,
respectively. Fifteen-year overall survival for patients having never
received DMT nor HSCTwas 95.4% (95%CI: 91–100; SE¼ 2.5%)
while for patients treated with HU or HSCT, overall survival was
respectively 99.4% (95%CI: 98–100; SE¼ 0.6%), and 93.8% (95%
CI: 89–99; SE¼ 2.7%). Kaplan–Meier estimates of survival
indicated that the three survival curves (HU, HSCT, and no DMT)
are different from each other (P¼ 0.046). Improved survival was
associated with HU compared with no DMT (P¼ 0.04) or with
HSCT (P¼ 0.01) while overall survival in HSCT patients was not
signiﬁcantly different from patients without DMT (P¼ 0.66).
Adjusted P-values for multiple testing remained signiﬁcant with
P¼ 0.013 and P¼ 0.003 for HU compared with no DMT or to
HSCT, respectively. No signiﬁcant time-varying effect of succes-
sive treatments could be found (P¼ 0.79).
DISCUSSION
Thanks to an observational multicenter design, the present work
provides important information about the outcome of a national
Belgian SCD cohort. Both children and adults diagnosed by
newborn screening or during a clinical event were included in the
study and data were collected prospectively or retrospectively. Our
main ﬁndings consisted in a globally low-mortality rate among the
entire cohort that did not signiﬁcantly increase above 18 years of
TABLE II. Data on Follow-Up and Mortality According to Last Treatment
Patients No DMT CT HU HSCT
N 170 24 185 90
Median age at diagnosis years (range) 0 (0–33) 1.0 (0–9.7) 1.2 (0–35) 1.9 (0–14.5)
Median age at last FU years (range) 7.6 (1.0–53) 12.2 (2.6–27) 13.7 (2.1–44) 16.9 (5.1–38)
Median FU years (range) 6.1 (0.1–49) 10.9 (2.3–25) 10.4 (0.1–35) 14.5 (1.3–32)
Follow-up (PY) 1,299 282 2,126 1,403
Lost of FU 16 0 10 4
Deaths 5 (2.9%) 0 3 (1.6%) 5 (5.6%)
Mortality-rate (/100 PY) 0.38 0 0.14 0.36
FU, follow-up; PY, patient-years; DMT, disease modifying treatment; CT, chronic transfusion; HU, hydroxyurea; HSCT, hematopoietic stem cell
transplantation. Median age at diagnosis, P-value<0.0001: No DMT versus HU*** and No DMT versus HSCT***. Median age at last FU, P-value
<0.0001: No DMT versus HU***, No DMT versus HSCT***, HU versus HSCT*. Median FU, P-value<0.0001: No DMT versus HU***, No DMT
versus HSCT***, No DMT versus CT*, HU versus HSCT**.
TABLE III. Causes of Death Reported in the National Belgian Database
Patient Sex Genotype Age at event Year of death Cause
1 F SS 11years 9 months 1992 Obliterans bronchiolitis/MOF on day103 post HSCT
2 F SS 22 years 4months 1994 Sepsis—Leg ulcer
3 M SS 7 years 1995 Secondary leukemia after extensive chronic graft
versus host disease 4.5 years after HSCT
4 M SS 17 years 7 months 1996 Unknown—Found dead at home 7 years after HSCT
5 F SS 18 months 1996 Cardiopulmonary arrest—Severe acute anemia episode
6 M SS 4 years 7 months 1999 Cardiac failure—Tetralogy of Fallot
7 M SS 26 months 2000 Septic shock on S. pmeumoniae septicaemia
8 F SS 14 years 9 months 2000 Hemorrhage diathesis/MOF on day 56 post HSCT
9 M SS 23 years 9 months 2003 Unknown—Died during holidays in Africa
10 M SS 14 years 3 months 2007 Meningeal hemorrhage
11 F SS 18 years 3 months 2007 Cerebral hemorrhage
12 F SS 18 years 9 months 2007 Cerebral aneurysm rupture
13 M SS 15 years 1 months 2011 Cerebral hemorrhage on day 18 post HSCT
MOF, multiple organ failure; HSCT: hematopoietic stem cell transplantation.
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age. Moreover, we observed a positive impact of HU treatment on
patients’ survival rate although the subjects under HU treatment
showed a longer length of follow-up and were older at the time of
SCD diagnosis. A possible explanation for this latter observation
was that HU prescription wasmostly supported by the succession of
SCD events overtime instead of resulting from a systematic use in
young children as recommended by the recent National Institutes of
Health guidelines.[34]
Our observedoverallmortality rate of 0.25 per 100patient years is
low. The mortality rates published and issued from single or
multicenter cohort studies are 0.13, 0.52, and 1.1 per 100 patient
years for theEast London cohort, theDallasNewbornCohort, and the
Cooperative Study on Sickle Cell Disease, respectively.[14–16,35]
These variable rates have been attributed to genetic differences in the
populations studied and also to the successful implementation of a
comprehensive care programme.[15,35] Compared to the East
London cohort, our population consisted of fewer HbSC individuals
(7% vs. 25%), a higher proportion of patients originating from
Central Africa, a region known to have more severe clinical SCD
forms (73%inour cohort), a highermedian age at last follow-up (12.3
years vs. 7.8 years), and a higher total follow-up duration (5,110
patient years vs. 2,158 patient years). As reported in the East London
cohort no deaths occurred in SC individuals with the current follow-
up.
During the last few decades, other interesting data were
provided from population-based analysis using national data
derived from death certiﬁcates in the United States. It highlights
the age-speciﬁc changes in mortality over time. As reported by
Yanni et al. (2009), from 1983–1986 to 1999–2002, the relative
mortality rate dropped signiﬁcantly in children younger than
10 years (and mainly under the age of four), but remained
unchanged in older ones. This survival improvement was
concurrent with the introduction of pneumococcal conjugate
vaccination suggesting that in addition to penicillin prescription,
conjugate vaccines might have strongly contributed to prevent
deaths from invasive pneumococcal infections.[3] A more recent
Fig. 1. Survival according to treatment.Kaplan–Meier curves show the 15-year overall survival for patients under hydroxyurea (HU), chronic transfusion
(CT), transplanted (HSCT), andwho do not received diseasemodifying therapy (DMT). The four survival curves are not signiﬁcantly different from each
other (P¼ 0.07). Patients receiving HU have a signiﬁcantly better survival in comparison to those without DMT treatment (P¼ 0.04) or those who have
been transplanted (P¼ 0.01). There was no signiﬁcant difference in survival among transplanted and untreated patients (P¼ 0.66).
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evaluation of mortality rates among United States children and
adults with SCD between two periods of time, i.e., 1979–1998 and
1999–2009, conﬁrmed the signiﬁcant decline in the mortality rate
among children but also among adolescents over time.[6]
Implementation of newborn screening, infection prophylaxis,
regular visits, and comprehensive care, as well as primary stroke
prevention policy most probably had an effect in the latter period.
However in adults no survival improvement was observed.[36] The
more recent population-based studies in the United States still
continue to show a signiﬁcantly higher rate of deaths attributable to
sickle cell disease in young adults compared to children or teenager.
The difﬁcult transition from pediatric to adult care with loss of
comprehensive care has been claimed to be themajor risk factor, but
poor socio-economic conditions, different cultural and educational
factors probably also have a role in that deterioration. The present
study, though limited, did not conﬁrm in the Belgian population the
dramatic increase in SCD-related mortality among young adults as
observed in the United States.[4,36] This suggests that the transition
may occur in better conditions with superior access to health care
under the Belgian health care system compared to that available in
the United States. Indeed the Belgian national healthcare system
contributes in a sameway to themedical costs irrespective of patient
age and employment. Furthermore, Belgium is a small country with
a high-medical density, a strong hematologists network that shares
standard of care, and patients who have direct access to specialists
and secondary or tertiary hospitals.
In addition to crude data on SCD mortality in Belgium, our
analyses provide information on speciﬁc outcome according to
therapeutic interventions. Hydroxyurea has beenwell described and
studied for more than two decades in adults and children.
[22,23,25,37–39] More recently, the BABY-HUG’s study[38,39]
showed evidence of safety and efﬁcacy data for HU therapy. It
decreased pain, dactylitis, chest acute syndrome, and hospitaliza-
tion, even for asymptomatic children. One considers that HU can be
safely offered in very young children with SCD too.[34] By several
mechanisms including increase in foetal hemoglobin production,
red cell hydration, reduction of the neutrophil, and the reticulocyte
counts, reduction of vascular adhesion molecules expression,
reduction of bone marrow cellularity, and improvement of nitric
oxide bioavaibility, it reduces the clinical severity of SCD course.
Actually, it is signiﬁcantly associated with reduction of acute pain
and ACS events in children and adults and might slow down the
development of organ dysfunction. The double blind, randomized
controlledMulticenter Study of Hydroxyurea trial provided the ﬁrst
data on clinical efﬁcacy of HU.[40] Adult patients with severe SCD
should have been treated for two years but clinical improvement for
patients on HU being much higher than for those without this
treatment, the trial was stopped early. After its closure, patients
could choose to stop, start, or continueHU.After a FU of 17.5 years,
43.1% of patients died (n¼ 129; 4.4 per 100-patient years). Eighty-
seven percent of patients who died were never exposed to HU or
took it for less than ﬁve years, suggesting that long-term use of HU
reduces mortality.[41] Voskaridou et al. (2010) also observed the
efﬁcacy of long-term treatment HU in adult SCD patients.
Signiﬁcant improvement in 10-year overall survival was associated
with HU treated compared to untreated ones who were not selected
to receive HU as they have been considered as having a milder
clinical disease. Signiﬁcant beneﬁt from HU treatment was
observed in SS and S/b˚-thalassemia genotypes but not in S/bþ-
thalassemia genotype.
Lobo et al. (2013) were the ﬁrst to investigate the impact of HU
on mortality in children treated with HU. Children with severe
disease, deﬁned as those with more than three painful events
requiring medical treatment, at least one episode of ACS, history of
stroke or transient ischemic attack, one serious or recurrent episode
of priapism, or an hemoglobin concentration <60 g/l on three
separate occasions, were eligible for HU treatment at a dose of
20mg/kg/day. One thousand seven hundred sixty patients were
included and followed during 7,925 patient years. Compared with
no treatment, in this study HU was highly beneﬁcial: one death
versus 36 (meaning 4.6 times less risk of dying), and amortality rate
per 100 patient years of 0.07 (0.08; HbSS and HbSb˚) versus 0.56
(0.59; HbSS and HbSb˚).
Even if our Belgian cohort is not exclusively issued from
newborn screening, the overall death rate is low (0.25/100 patient
years) and remains low when considering only patients with SS and
Sb˚ genotypes (0.27/100 patient years). Several methodological
biases are present in this partially retrospective study: no
population-based study, incomplete, or unavailability of some
ﬁles, loss of follow-up that occurred in 30 patients and no
information if death occurred before the ﬁrst contact in a center.
Nevertheless, this probably does not alter our ﬁgures because (1)
most patients have been followed since early childhood and for a
long period of time cumulating 5,110 patient-years; (2) the follow-
up during adulthood, when burden of mortality increases,
accounted for 1,019 patient years; (3) data of the patients followed
in the eight participating centers could be easily retrieved from their
medical record and from the date of their diagnosis; and (4) our
cohort represents a very large part of the Belgian population with
SCD. In the absence of a national-based neonatal screening
program and/or ofﬁcial registration based on diagnosis, the total
number of SCD living in Belgium is unknown. A national inquiry
performed in 2008 estimated the total number of patient with severe
hemoglobinopathy to be 417 from whom 83% were sickle cell
patients.[42] Our data concern thus a large majority of regularly
monitored patients living in Belgium.
The 13 deaths reported in our cohort were related either to an
acute event (8/13) or to HSCT toxicity (5/13). Cerebral hemorrhage
remains the leading cause of death followed by infection. Mortality
due to complications following HSCTaccounted for more than one-
third of all deaths resulting in lower survival in transplanted
children when compared to those on HU. This might reﬂect some
selection bias and differences in severity as HSCT is generally
indicated in patients with a more severe clinical disease.
Nevertheless, we could not demonstrate a more severe clinical
disease in patients having been transplanted: they had signiﬁcantly
less VOC and similar history of ACS, stroke, or risk for strokewhen
compared to the HU group. The comparison of our relatively large
group of patients treated with stem cell transplantation to those
receiving other therapies failed to demonstrate any beneﬁt of HSCT
in terms of survival. However, death rate provides a very incomplete
picture of the relative beneﬁt of HSCT since long-term beneﬁt may
compensate the existing upfront mortality. Cure of SCD is now
achieved in 95% of patients[29,30] and most of the successfully
transplanted patients have improved quality of life. Prospective or
cross-sectional comparisons of quality of life in the various
treatment modalities could not be performed in the context of our
registry and would provide strong data on the long-term beneﬁts of
transplantation compared to other treatment strategies. A longer
follow-up, during adulthood when SCD morbidity and mortality
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increase[43,44] is also mandatory to prove if previously trans-
planted patients will be advantaged for long-term survival
compared to un-transplanted individuals treated with HU. The
main limitations of our analysis were the combination of a
prospective and retrospective design, the absence of population-
based data, the monocentric data collection, and the absence of
standardization in treatment decision making.
In conclusion, whereas several studies have suggested a beneﬁt
from hydroxyurea treatment on children and adult sickle cell
patients’ survival, our study pointed out the positive impact during
childhood. No beneﬁt of HSCT versus HU on survival rate could be
demonstrated after a 15 years median follow-up, but long-term,
multicentric surveillance is required with help of the SCD Belgian
National Registry. Finally, our results suggest that the availability of
efﬁcient alternatives in SCD treatment might render less systematic
the need for HSCT that could be at least postponed in young patients
with mild disease.
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